Literature DB >> 34072937

Organoboron Compounds: Effective Antibacterial and Antiparasitic Agents.

Paolo Saul Coghi1, Yinghuai Zhu2, Hongming Xie2, Narayan S Hosmane3, Yingjun Zhang2.   

Abstract

The unique electron deficiency and coordination property of boron led to a wide range of applications in chemistry, energy research, materials science and the life sciences. The use of boron-containing compounds as pharmaceutical agents has a long history, and recent developments have produced encouraging strides. Boron agents have been used for both radiotherapy and chemotherapy. In radiotherapy, boron neutron capture therapy (BNCT) has been investigated to treat various types of tumors, such as glioblastoma multiforme (GBM) of brain, head and neck tumors, etc. Boron agents playing essential roles in such treatments and other well-established areas have been discussed elsewhere. Organoboron compounds used to treat various diseases besides tumor treatments through BNCT technology have also marked an important milestone. Following the clinical introduction of bortezomib as an anti-cancer agent, benzoxaborole drugs, tavaborole and crisaborole, have been approved for clinical use in the treatments of onychomycosis and atopic dermatitis. Some heterocyclic organoboron compounds represent potentially promising candidates for anti-infective drugs. This review highlights the clinical applications and perspectives of organoboron compounds with the natural boron atoms in disease treatments without neutron irradiation. The main topic focuses on the therapeutic applications of organoboron compounds in the diseases of tuberculosis and antifungal activity, malaria, neglected tropical diseases and cryptosporidiosis and toxoplasmosis.

Entities:  

Keywords:  anti-cancer drug; anti-malaria drug; anti-tuberculosis; crypto and toxoplasmosis treatment; neglected tropical disease; organoboron compound

Year:  2021        PMID: 34072937     DOI: 10.3390/molecules26113309

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  95 in total

Review 1.  Boron-based drugs as antiprotozoals.

Authors:  Robert T Jacobs; Jacob J Plattner; Martine Keenan
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

Review 2.  New therapeutic options for onychomycosis.

Authors:  Aditya K Gupta; Fiona C Simpson
Journal:  Expert Opin Pharmacother       Date:  2012-04-25       Impact factor: 3.889

3.  Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei.

Authors:  Puhua Wu; Jiong Zhang; Qingqing Meng; Bakela Nare; Robert T Jacobs; Huchen Zhou
Journal:  Eur J Med Chem       Date:  2014-04-29       Impact factor: 6.514

Review 4.  Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets.

Authors:  Alane B Vermelho; Giseli R Capaci; Igor A Rodrigues; Verônica S Cardoso; Ana Maria Mazotto; Claudiu T Supuran
Journal:  Bioorg Med Chem       Date:  2017-01-24       Impact factor: 3.641

5.  Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents.

Authors:  Dazhong Ding; Qingqing Meng; Guangwei Gao; Yaxue Zhao; Qing Wang; Bakela Nare; Robert Jacobs; Fernando Rock; Michael R K Alley; Jacob J Plattner; Guoqiang Chen; Dawei Li; Huchen Zhou
Journal:  J Med Chem       Date:  2011-02-15       Impact factor: 7.446

Review 6.  Global causes of diarrheal disease mortality in children <5 years of age: a systematic review.

Authors:  Claudio F Lanata; Christa L Fischer-Walker; Ana C Olascoaga; Carla X Torres; Martin J Aryee; Robert E Black
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

7.  Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.

Authors:  Andrés Palencia; Ru-Juan Liu; Maria Lukarska; Jiri Gut; Alexandre Bougdour; Bastien Touquet; En-Duo Wang; Xianfeng Li; M R K Alley; Yvonne R Freund; Philip J Rosenthal; Mohamed-Ali Hakimi; Stephen Cusack
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis.

Authors:  Aaron Korkegian; Theresa O'Malley; Yi Xia; Yasheen Zhou; David S Carter; Bjorn Sunde; Lindsay Flint; Dean Thompson; Thomas R Ioerger; Jim Sacchettini; M R K Alley; Tanya Parish
Journal:  Tuberculosis (Edinb)       Date:  2017-11-07       Impact factor: 3.131

Review 9.  Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications.

Authors:  Mariana Pereira Silva; Lucília Saraiva; Madalena Pinto; Maria Emília Sousa
Journal:  Molecules       Date:  2020-09-21       Impact factor: 4.411

10.  Cuts in cancer research funding due to COVID-19.

Authors:  Talha Khan Burki
Journal:  Lancet Oncol       Date:  2020-12-17       Impact factor: 54.433

View more
  4 in total

Review 1.  Biosynthesis and Chemical Synthesis of Albomycin Nucleoside Antibiotics.

Authors:  Meiyan Wang; Yuxin Zhang; Lanxin Lv; Dekun Kong; Guoqing Niu
Journal:  Antibiotics (Basel)       Date:  2022-03-24

Review 2.  Merging Electron Deficient Boronic Centers with Electron-Withdrawing Fluorine Substituents Results in Unique Properties of Fluorinated Phenylboronic Compounds.

Authors:  Agnieszka Adamczyk-Woźniak; Andrzej Sporzyński
Journal:  Molecules       Date:  2022-05-26       Impact factor: 4.927

3.  Functionalized Boron Nanoparticles as Potential Promising Antimalarial Agents.

Authors:  Yinghuai Zhu; Parichat Prommana; Narayan S Hosmane; Paolo Coghi; Chairat Uthaipibull; Yingjun Zhang
Journal:  ACS Omega       Date:  2022-02-09

Review 4.  New Insights into Boron Essentiality in Humans and Animals.

Authors:  Andrei Biţă; Ion Romulus Scorei; Tudor Adrian Bălşeanu; Maria Viorica Ciocîlteu; Cornelia Bejenaru; Antonia Radu; Ludovic Everard Bejenaru; Gabriela Rău; George Dan Mogoşanu; Johny Neamţu; Steven A Benner
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.